State Street’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $56.6M | Sell |
11,179,539
-1,905,719
| -15% | -$9.64M | ﹤0.01% | 1610 |
|
|
2025
Q1 | $69.2M | Buy |
13,085,258
+506,898
| +4% | +$2.68M | ﹤0.01% | 1474 |
|
|
2024
Q4 | $85M | Sell |
12,578,360
-291,912
| -2% | -$1.97M | ﹤0.01% | 1440 |
|
|
2024
Q3 | $84.8M | Buy |
12,870,272
+4,120,685
| +47% | +$27.2M | ﹤0.01% | 1418 |
|
|
2024
Q2 | $65.6M | Sell |
8,749,587
-1,602,769
| -15% | -$12M | ﹤0.01% | 1517 |
|
|
2024
Q1 | $103M | Sell |
10,352,356
-1,799,290
| -15% | -$17.9M | ﹤0.01% | 1284 |
|
|
2023
Q4 | $120M | Buy |
12,151,646
+394,558
| +3% | +$3.89M | 0.01% | 1172 |
|
|
2023
Q3 | $89.9M | Buy |
11,757,088
+6,059,156
| +106% | +$46.4M | 0.01% | 1252 |
|
|
2023
Q2 | $42.6M | Sell |
5,697,932
-674,583
| -11% | -$5.04M | ﹤0.01% | 1768 |
|
|
2023
Q1 | $42.5M | Sell |
6,372,515
-1,498,443
| -19% | -$9.99M | ﹤0.01% | 1759 |
|
|
2022
Q4 | $60.7M | Buy |
7,870,958
+3,315,199
| +73% | +$25.6M | ﹤0.01% | 1500 |
|
|
2022
Q3 | $48.5M | Buy |
4,555,759
+2,430,027
| +114% | +$25.9M | ﹤0.01% | 1616 |
|
|
2022
Q2 | $17.3M | Buy |
2,125,732
+206,998
| +11% | +$1.68M | ﹤0.01% | 2353 |
|
|
2022
Q1 | $13.7M | Sell |
1,918,734
-2,737,993
| -59% | -$19.6M | ﹤0.01% | 2645 |
|
|
2021
Q4 | $79.8M | Buy |
4,656,727
+3,012,233
| +183% | +$51.6M | ﹤0.01% | 1471 |
|
|
2021
Q3 | $37.8M | Buy |
1,644,494
+1,267,062
| +336% | +$29.2M | ﹤0.01% | 2013 |
|
|
2021
Q2 | $13.8M | Buy |
+377,432
| New | +$13.8M | ﹤0.01% | 2722 |
|